Galderma Group AG
GALD
Company Profile
Business description
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
Contact
Zahlerweg 10
Zug6300
CHET: +41 584558592
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
7,600
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.50 | 69.70 | -0.75% |
| CAC 40 | 8,368.91 | 7.55 | 0.09% |
| DAX 40 | 26,749.95 | 21.93 | -0.08% |
| Dow JONES (US) | 52,347.55 | 50.46 | 0.10% |
| FTSE 100 | 10,902.56 | 39.47 | 0.36% |
| HKSE | 23,637.60 | 370.95 | -1.55% |
| NASDAQ | 25,136.27 | 229.82 | -0.91% |
| Nikkei 225 | 61,142.35 | 322.99 | 0.53% |
| NZX 50 Index | 14,173.68 | 85.55 | -0.60% |
| S&P 500 | 7,561.67 | 30.73 | -0.40% |
| S&P/ASX 200 | 9,082.20 | 64.60 | -0.71% |
| SSE Composite Index | 3,634.35 | 21.48 | -0.59% |